Sam Altman's Longevity Startup Is Testing a Pill for a Younger Brain

Sam Altman’s longevity startup is testing a pill for a younger brain

Joe Betts-LaCroix is the CEO of Retro Biosciences, a longevity startup backed with cash from OpenAI’s Sam Altman. Justin Winokur Photography Retro Biosciences is a longevity startup backed by OpenAI’s CEO, Sam Altman. Retro’s said its first human clinical trial is set to launch by the end of 2025. It’s for a pill designed to clear out “gunk” in the brain and reverse Alzheimer’s. I’ve just hopped on a video call with the CEO of Retro Biosciences…

Sam Altman's longevity startup is testing a pill for a younger brain

Joe Betts-LaCroix is the CEO of Retro Biosciences, a longevity startup backed with cash from OpenAI's Sam Altman.Justin Winokur PhotographyRetro Biosciences is a longevity startup backed by OpenAI's CEO, Sam Altman.Retro's said its first human clinical trial is set to launch by the end of 2025.It's for a pill designed to clear out "gunk" in the brain and reverse Alzheimer's.I've just hopped on a video call with the CEO of Retro Biosciences, the …

Sam Altman-Backed Retro Biosciences Raises $1B for 10-Year Healthspan Extension

In the bustling world of biotechnology, few ventures capture the imagination quite like Retro Biosciences, the San Francisco-based startup backed by OpenAI CEO Sam Altman. Founded in 2021, the company has set an audacious goal: to extend the human healthspan by a full decade, focusing on therapies that combat the cellular hallmarks of aging. Altman’s personal investment of $180 million in 2022 underscores his belief in this mission, as detailed …